Apitegromab - Scholar Rock
Alternative Names: SRK-015Latest Information Update: 11 Mar 2026
At a glance
- Originator Scholar Rock
- Class Monoclonal antibodies; Obesity therapies
- Mechanism of Action Myostatin inhibitors
-
Orphan Drug Status
Yes - Spinal muscular atrophy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Spinal muscular atrophy
- Phase II Obesity
- Phase I Facioscapulohumeral muscular dystrophy
- No development reported Muscular atrophy; Spinal cord injuries
Most Recent Events
- 03 Mar 2026 Scholar Rock plans to resubmit the BLA to the US FDA for apitegromab for Spinal muscular atrophy (In children, In adults) in 2026
- 03 Mar 2026 Scholar Rock expects approval of Apitegromab for Spinal muscular atrophy by the EMA in mid-2026
- 03 Mar 2026 Scholor Rock plans phase-II FORGE trial for Facioscapulohumeral muscular dystrophy (IV, Infusion) in August 2026 (NCT07435129)